Preclinical characterization of DK-AT390HCl, a potent PIKfyve inhibitor in colorectal cancer models

PIKfyve regulates endolysosomal trafficking and late-stage autophagic processing, making it a therapeutic target in pathway-dependent tumors. This study characterized the preclinical activity, target-binding profile, pharmacokinetics, and antitumor efficacy of the 1,3,5-triazine derivative DK-AT390HCl in colorectal cancer models. DK-AT390HCl bound PIKfyve with high affinity ( K d = 5.6 nM), inhibited its kinase activity in an ADP-Glo assay (IC₅₀ = 21.5 nM) and showed favorable kinase-panel selectivity. It inhibited proliferation of murine CT26 and human SW480 and SW620 cells, with IC 50 values of 8.6–15.9 µM, while 50% growth inhibition was not reached in non-malignant colonic epithelial cells or murine fibroblasts. The compound also reduced clonogenic and CT26 spheroid growth. Treatment induced pronounced vacuolization, accumulation of MDC-positive vesicles, changes in LC3B-II, p62, and ATG5, and reduced FOXM1 abundance, consistent with altered endolysosomal and autophagy-associated processing. DK-AT390HCl achieved measurable systemic exposure. In an orthotopic CT26 model, tumor volume and tumor burden were numerically lower in all treated groups than in untreated controls, but these differences reached statistical significance only for the combination of DK-AT390HCl with 5-fluorouracil after correction for multiple comparisons. These findings identify DK-AT390HCl as a promising starting point for PIKfyve-directed colorectal cancer drug discovery, while further target validation and optimization of cellular potency, solubility, and metabolic stability remain necessary.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2026-11-16
DOI
https://doi.org/10.1016/j.biopha.2026.120061
Primary Topic
Autophagy in Disease and Therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Preclinical characterization of DK-AT390HCl, a potent PIKfyve inhibitor in colorectal cancer models

Damian Kułaga, Laura Pardyak, Emilia Samborowska, Krzesimir Ciura et al.
3 links
Biomedicine & Pharmacotherapy
Autophagy in Disease and Therapy
article

Preclinical characterization of DK-AT390HCl, a potent PIKfyve inhibitor in colorectal cancer models

Damian Kułaga, Laura Pardyak, Emilia Samborowska, Krzesimir Ciura, Paweł Szczerbik, Izabela Siemińska, Gniewomir Latacz, Marta Kot, Zbigniew Arent
article en

Abstract

PIKfyve regulates endolysosomal trafficking and late-stage autophagic processing, making it a therapeutic target in pathway-dependent tumors. This study characterized the preclinical activity, target-binding profile, pharmacokinetics, and antitumor efficacy of the 1,3,5-triazine derivative DK-AT390HCl in colorectal cancer models. DK-AT390HCl bound PIKfyve with high affinity ( K d = 5.6 nM), inhibited its kinase activity in an ADP-Glo assay (IC₅₀ = 21.5 nM) and showed favorable kinase-panel selectivity. It inhibited proliferation of murine CT26 and human SW480 and SW620 cells, with IC 50 values of 8.6–15.9 µM, while 50% growth inhibition was not reached in non-malignant colonic epithelial cells or murine fibroblasts. The compound also reduced clonogenic and CT26 spheroid growth. Treatment induced pronounced vacuolization, accumulation of MDC-positive vesicles, changes in LC3B-II, p62, and ATG5, and reduced FOXM1 abundance, consistent with altered endolysosomal and autophagy-associated processing. DK-AT390HCl achieved measurable systemic exposure. In an orthotopic CT26 model, tumor volume and tumor burden were numerically lower in all treated groups than in untreated controls, but these differences reached statistical significance only for the combination of DK-AT390HCl with 5-fluorouracil after correction for multiple comparisons. These findings identify DK-AT390HCl as a promising starting point for PIKfyve-directed colorectal cancer drug discovery, while further target validation and optimization of cellular potency, solubility, and metabolic stability remain necessary.

Biomedicine & PharmacotherapyVol. 205
Jagiellonian University (PL), University of Agriculture in Krakow (PL), Cracow University of Technology (PL), Institute of Biochemistry and Biophysics, Polish Academy of Sciences (PL), Gdańsk Medical University (PL), Polish Academy of Sciences (PL)
Fundacja na rzecz Nauki Polskiej, Narodowe Centrum Badań i Rozwoju
Good health and well-being
Autophagy in Disease and Therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon